DDInter526 DDInter1376
Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dextroamphetamine {u} (Compound) resembles {v} (Compound) Fenproporex
Dextroamphetamine {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Dextroamphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Dextroamphetamine {u} (Compound) binds {v} (Gene) SLC6A2
Dextroamphetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Dextroamphetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Dextroamphetamine {u} (Compound) causes {v} (Side Effect) Photosensitivity reaction
Dextroamphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Dextroamphetamine {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Dextroamphetamine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Dextroamphetamine (Compound) resembles Fenproporex (Compound)
Dextroamphetamine (Compound) resembles L-Phenylalanine (Compound)
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Dextroamphetamine (Compound) binds SLC6A2 (Gene)
Dextroamphetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Dextroamphetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Dextroamphetamine (Compound) causes Photosensitivity reaction (Side Effect)
Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Dextroamphetamine may lead to a major life threatening interaction when taken with Methylene blue
Dextroamphetamine may lead to a major life threatening interaction when taken with Fenfluramine